DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
AT9283 is an investigational drug.
There have been 5 clinical trials for AT9283. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2010.
The most common disease conditions in clinical trials are Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, and Lymphoma, Non-Hodgkin. The leading clinical trial sponsors are NCIC Clinical Trials Group, Cancer Research UK, and Astex Pharmaceuticals.
Recent Clinical Trials for AT9283
|AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia||Cancer Research UK||Phase 1|
|A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma||NCIC Clinical Trials Group||Phase 2|
|AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors||Cancer Research UK||Phase 1|